Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares fell 7.2% on Wednesday . The stock traded as low as GBX 7.37 ($0.10) and last traded at GBX 7.70 ($0.10). 2,541,886 shares changed hands during mid-day trading, an increase of 44% from the average session volume of 1,765,747 shares. The stock had previously closed at GBX 8.30 ($0.11).
Poolbeg Pharma Trading Down 7.2 %
The firm has a fifty day moving average of GBX 11.07 and a two-hundred day moving average of GBX 11.88. The company has a market cap of £38.50 million, a PE ratio of -775.00 and a beta of 2.12.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Stories
- Five stocks we like better than Poolbeg Pharma
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Momentum Trades for October With Ample Upside Ahead
- What Are Dividend Achievers? An Introduction
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What is the S&P 500 and How It is Distinct from Other Indexes
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
